Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 May;53(5):2189-91.
doi: 10.1128/AAC.01091-08. Epub 2009 Feb 23.

Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women

Tim R Cressey  1 , Russell Van Dyke, Gonzague Jourdain, Thanyawee Puthanakit, Anuvat Roongpisuthipong, Jullapong Achalapong, Prapap Yuthavisuthi, Sinart Prommas, Nantasak Chotivanich, Robert Maupin, Elizabeth Smith, David E Shapiro, Mark Mirochnick; IMPAACT P1032 Team
Collaborators, Affiliations

Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women

Tim R Cressey et al. Antimicrob Agents Chemother. 2009 May.

Abstract

Lopinavir (LPV) exposure is reduced during the third trimester of pregnancy. We report the pharmacokinetics of standard LPV-ritonavir dosing (400/100 mg twice daily) in the immediate and early postpartum period when initiated during labor. In 16 human immunodeficiency virus-infected Thai women, the median (range) LPV area under the concentration-time curve and maximum and minimum concentrations in plasma were 99.7 (66.1 to 180.5) microg x h/ml, 11.2 (8.0 to 17.5) microg/ml, and 4.6 (1.7 to 12.5) microg/ml, respectively, at 41 (12 to 74) h after delivery. All of the women attained adequate LPV levels through 30 days postpartum. No serious adverse events were reported.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Individual plasma LPV concentration-time curves within 72 h postpartum for 16 HIV-infected Thai women who initiated LPV/r (400/100 mg twice daily) intrapartum.
See this image and copyright information in PMC

References

    1. Chi, B. H., M. Sinkala, F. Mbewe, R. A. Cantrell, G. Kruse, N. Chintu, G. M. Aldrovandi, E. M. Stringer, C. Kankasa, J. T. Safrit, and J. S. Stringer. 2007. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 370:1698-1705. - PubMed
    1. Droste, J. A., C. P. Verweij-Van Wissen, and D. M. Burger. 2003. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther. Drug Monit. 25:393-399. - PubMed
    1. Gibbons, S., D. Back, and S. Khoo. 2007. Variability in lopinavir concentrations in the clinical setting and factors affecting concentrations, abstr. 37. Eighth International Workshop on Clinical Pharmacology of HIV Infection, Budapest, Hungary, April 2007.
    1. McIntyre, J., N. Martinson, Investigators for the Trial 1413, V. Boltz, S. Palmer, J. Coffin, J. Mellors, M. Hopley, T. Kimura, P. Robinson, and D. Mayers. 2004. Addition of short course combivir (CBV) to single dose viramune (sdNVP) for prevention of mother-to-child transmission (MTCT) of HIV-1 can significantly decrease the subsequent development of maternal NNRTI-resistant virus, abstr. LbOrB09. XV International AIDS Conference, Bangkok, Thailand, 11 to 16 July 2004.
    1. Murphy, R. L., S. Brun, C. Hicks, J. J. Eron, R. Gulick, M. King, A. C. White, Jr., C. Benson, M. Thompson, H. A. Kessler, S. Hammer, R. Bertz, A. Hsu, A. Japour, and E. Sun. 2001. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 15:F1-F9. - PubMed

Publication types

MeSH terms